Skip to main content
Evidence Snapshot

B-cell lymphoma/leukemia 11A

CHEMBL5498502 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:55:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5498502
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats B-cell lymphoma/leukemia 11A as ChEMBL target CHEMBL5498502, mapped to UniProt Q9H165. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
B-cell lymphoma/leukemia 11A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5498502
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9H165
BCL11 transcription factor A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why B-cell lymphoma/leukemia 11A matters

As of 2026-09-13

B-cell lymphoma/leukemia 11A is reviewed as BCL11 transcription factor A (UniProt Q9H165); B-cell lymphoma/leukemia 11A shows approved-linked disease relevance led by Beta-thalassemia. 3 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded..

Protein context
BCL11 transcription factor A

BCL11 transcription factor A Sequence length is 835 aa.

Review this target as B-cell lymphoma/leukemia 11A, mapped to UniProt Q9H165. ChEMBL maps the protein component as BCL11 transcription factor A. Sequence length is 835 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9H165 Protein
Disease context
Beta-thalassemia

B-cell lymphoma/leukemia 11A shows approved-linked disease relevance led by Beta-thalassemia. 3 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include EXAGAMGLOGENE AUTOTEMCEL.

Start review with Beta-thalassemia because it currently carries approved-linked support. Linked drugs include EXAGAMGLOGENE AUTOTEMCEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why B-cell lymphoma/leukemia 11A matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9H165, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Beta-thalassemia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

0
Total Compounds
0
Total Assays
0
Approved Drugs
-
Activity Types

pChEMBL Activity Distribution

← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:55:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5498502